ACAM2000 market forecast points to steady growth through 2035

The Business Research Company says the ACAM2000 market will expand through 2035 as governments boost biodefense, stockpile vaccines and respond to renewed mpox and other orthopoxvirus threats. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - ACAM2000 sits at the center of biodefense and infectious disease preparedness. - Demand is tied to government stockpiling, military vaccination programs and outbreak response planning. - The market outlook matters for public health agencies that need vaccine reserves for smallpox and mpox risks.

What happened: - The Business Research Company released its ACAM2000 Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report was published Nov. 1, 2026. - The report says the ACAM2000 market is positioned for steady growth. - The report says renewed mpox outbreaks, biodefense funding and vaccine procurement programs are supporting demand. - The report includes a free sample and the full market report here and here.

The details: - ACAM2000 is a live vaccinia virus vaccine authorized by the Food and Drug Administration for use against smallpox. - The vaccine is mainly used for people at higher risk, including military members and laboratory staff working with orthopoxviruses. - The vaccine works by introducing a weakened virus closely related to smallpox to help the immune system build protection. - The report says earlier market growth was driven by smallpox eradication efforts, biodefense programs, military vaccination requirements, regulatory approvals and public health preparedness policies. - The report expects future growth from emergency vaccine stockpiles, government vaccine procurement and national biosecurity strategies. - Expected trends include strategic stockpiling, government-managed vaccine distribution, focused immunization of high-risk groups and readiness for emerging orthopoxvirus threats. - The report says infectious disease growth is a major market driver. - The report points to rising global travel as a factor that speeds pathogen transmission across borders. - The UK Health Security Agency reported in February 2024 that tuberculosis cases in England rose 10.7% in 2023 versus the prior year. - The report says higher healthcare spending is also supporting ACAM2000 purchases, stockpiling and distribution. - The UK Office for National Statistics reported in May 2024 that total healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023. - The same ONS report said long-term health and social care spending increased 2.8% in real terms during 2022. - In 2025, North America held the largest share of the ACAM2000 market. - The report says Asia-Pacific will likely be the fastest-growing region in the coming years. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market thesis is less about routine vaccination and more about readiness for rare but high-consequence threats. - Government budgets and procurement decisions appear to be the main demand engine. - The emphasis on stockpiles suggests agencies are planning for surge response instead of broad civilian use.

What's next: - The report points to continued buying tied to biodefense planning and outbreak preparedness. - Governments are likely to keep expanding emergency reserves and distribution plans. - The report also highlights updated market tools, including TAM analysis, company scoring matrices, forecasting dashboards and trend graphics. - The Business Research Company lists Saumya Sahay as a contact for more information, with regional phone numbers and marketing@tbrc.info. - The company also directs readers to its LinkedIn page and other social channels.